Back

The effect of spironolactone on infections in heart failure with preserved ejection fraction

17 May 2025 (08:00 - 12:45)
Organised by: Logo
Congress Presentation Part of: Heart failure in the era of precision medicine: insights into pathophysiology and emerging treatments Heart Failure with Preserved Ejection Fraction (HFpEF) HFA Premium Access Heart Failure 2025 Heart Failure Association (HFA)

About the speaker

Photo
Doctor Barna Szabo-Soderberg

Karolinska Institute, Stockholm (Sweden)

5 More presentations in this session

Presentation thumbnail
Body mass related epigenetic reprogramming and downstream analysis in heart failure phenotypes
Miss E. Yapici (Mainz, DE)
Abstract Slides Video
Presentation thumbnail
Long COVID: insights from echocardiography, cardiac magnetic resonance, and endomyocardial Biopsies in previous healthy individuals with persistent chest pain
Doctor O. Gomez Monterrosas (Puebla, MX)
Abstract Slides Video
Presentation thumbnail
A characterisation of mitochondrial structure, oxidative phosphorylation capacity, and amyloid burden in patients with wild-type transthyretin cardiomyopathy
Doctor B. Ladefoged (Aarhus, DK)
Abstract Slides Video
Presentation thumbnail
Beneficial metabolic effects of 2-week ketone ester in patients with type 2 diabetes and heart failure with preserved ejection fraction.
Doctor N. Gopalasingam (Aarhus, DK)
Abstract Slides Video
Presentation thumbnail
Systemic microvascular dysfunction in heart failure with preserved ejection fraction: the PROSE-HFpEF case-control study
Doctor J. Weerts (Maastricht, NL)
Abstract Slides Video

Access the full session

Session thumbnail
Heart failure in the era of precision medicine: insights into pathophysiology and emerging treatments
Video

The Event

Event poster

Heart Failure 2025

17 May - 20 May 2025
You may be interested in
thumbnail
Congress Presentation
Panel discussion and conclusion
thumbnail
Congress Presentation
Mineralocorticoid receptor antagonist therapy in patients with ischemic heart failure and ventricular tachycardia: a comparative analysis of spironolactone vs. eplerenone
thumbnail
Congress Presentation
Efficacy of spironolactone in reducing the risk of cardiovascular events and long-term mortality in those with resistant hypertension: findings from the Anglo-Scandinavian Cardiac Outcomes Trial.

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources